Theriva Biologics, Inc.
Here’s whether Theriva Biologics, Inc. (TOVX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+6.78% over 10 days); RSI 40 — healthy momentum range; 3-month momentum positive (+39.4%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -45.8%. Currently 70.4% off its 52-week high. Score: -1/7.
TOVX is trading below its 200-day MA ($0.29) — a key warning sign the longer-term trend is under pressure. An RSI of 40.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -45.8% compares to +24.4% for SPY (trailed the market by 70.2%). The current 70.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.